
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in Europe and Latin America
The mRNA vaccines against SARS-CoV-2 have protected billions of people worldwide, but the novel variants of concern (VoC) could escape
We have a team of safety scientists and physicians supporting a wide range of pharmacovigilance (PV) services. Our activities range from auditing/quality assessment, to post-marketing and clinical safety.
The mRNA vaccines against SARS-CoV-2 have protected billions of people worldwide, but the novel variants of concern (VoC) could escape
Human Papillomaviruses (HPVs) are the primary pathogens causing anal cancers, accounting for nearly 90% of global cases. The HPV-associated anal
We offer a wide range of projects. Click on the icons below for more info.
End-to-end clinical trial services in different therapeutic areas
Study conduct, analysis and reporting
All stages from protocol to publication
Epidemiology, medical writing, statistics/IT and qualitative research